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Abstract 
Pseudomyxoma peritonei is only rarely seen in conjunction with primary ovarian tumors. 
It has been suggested that only ruptured mucinous tumors arising in ovarian mature 
cystic teratomas can result in this clinical picture. We describe a case of a late invasive 
recurrence of a mucinous intestinal-type borderline ovarian tumor arising from a mature 
teratoma after complete surgical debulking. Borderline ovarian tumors behave indolently 




Pseudomyxoma peritonei (PMP) is a rare entity characterized by mucinous ascites, 
peritoneal implants of mucin and abdominal neoplasms. PMP diagnosed pathologically 
as disseminated peritoneal adenomucinosis (DPAM) is only rarely seen in conjunction 
with primary ovarian tumors [1]. Some authors claim that only ruptured mucinous 
tumors arising in ovarian mature cystic teratomas, which likely arise from endoderm-
derived elements of the teratoma, can result in a clinical picture of PMP [1, 2]. The 
recurrence risk of mucinous tumors arising in ovarian teratomas, particularly those with 
associated PMP, is not known [3]. Case Rep Oncol 2011;4:426–432 
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Published online: 
August 31, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–6575 





We encountered a late invasive recurrence of a mucinous intestinal-type ovarian 
borderline tumor arising from a mature teratoma after complete surgical debulking. 
Case Report 
We describe a case of a 59-year-old woman with an uneventful medical history, apart from morbid 
obesity (body mass index of 48). She presented with abdominal fullness, umbilical herniation and 
dyspnea. CT scan revealed an ovarian mass and ascites. Cancer antigen 125 (CA125) tumor marker 
analysis was below detection threshold. Surgical exploration by median laparotomy showed widespread 
gelatinous mucinous ascites (PMP) and a huge ruptured right ovarian tumor of 30 cm in diameter. The 
patient underwent a subtotal abdominal hysterectomy, bilateral salpingo-oophorectomy, 
appendectomy, omentectomy, umbilical herniorrhaphy and resection of all visible mucinous deposits. 
Anatomopathological examination revealed a ruptured right ovary with a mucinous borderline 
cystadenocarcinoma arising within a mature teratoma and a DPAM in accordance with Ronnett [1]. It 
contained a multiloculated mucinous cystic tumor within which a 12-cm mature cystic teratoma was 
embedded. Microscopically, multiple cysts were seen covered with mucinous epithelium. Goblet cells 
were seen as well as pseudo-multiple layered epithelium. Focally the stroma had a myxoid aspect. In 
some sections the ectodermal component was present. Coexpression of CK 7 and CK20 was noticed by 
immunohistochemistry (fig. 1, fig. 2). 
The left ovary was uninvolved. The ascites and peritoneal implants were composed of abundant 
mucin devoid of mucinous epithelium. The appendix was examined histologically and was found to be 
entirely normal. Omentum, umbilical hernia sac and mesoappendix were found to contain mucin pools. 
The postoperative recovery was uneventful. No adjuvant therapy was given subsequently. 
Radiological imaging three months after surgery indicated neither the presence of ascites nor tumoral 
relapse. The patient moved abroad and was lost for follow-up. Fifty-four months postoperatively she 
was again seen at the outpatient clinic with complaints of an umbilical hernia increasing in size over the 
past year. Clinically the patient presented with a hard spherical mass in the umbilical hernia sac 
measuring 14 cm. CA125 tumor marker testing was still negative. An abdominal CT scan showed a 
diffuse intra-abdominal collection also spreading through the umbilical herniation forming a spherical 
subcutaneous mass. A relapse of pseudomyxoma, with peritoneal carcinomatosis and a bulging 
umbilical hernia containing mucinous pools, was suspected (fig. 3, fig. 4). 
Surgical exploration revealed a massive umbilical herniation filled by a solid mucinous tumor, 
attached to the abdominal fascia. After surgical resection, approximately 10 liters of gelatinous 
mucinous ascites was drained. Inspection of the peritoneal cavity demonstrated disseminated peritoneal 
carcinomatosis with invasive implants widespread on the peritoneum, small intestine, colon, 
diaphragm, liver and stomach. One further solitary nodule of 10 cm on the colon ascendens was 
resected. The umbilical hernia sac was resected and the abdominal fascia was closed classically. 
After a partial resection of the rectal fascia to liberate the hard spherical mass, a complete surgical 
debulking was judged to be technically impossible. The abdominal wall was sutured by using two 
Ventrofil (B. Braun, Melsungen, Germany) sutures for prevention of abdominal wound dehiscence in 
this obese patient. 
Anatomopathological examination showed multiple metastases of a mucinous cystadenocarcinoma. 
At microscopic examination the metastases showed large pools filled with mucin enveloped by smooth 
connective tissue while the hard spherical mass consisted of small mucinous pools incorporated within 
dense fibrous tissue partitions. 
Postoperatively no major wound complication occurred and 6 weeks later the first cycle of 
Carboplatinum-Taxol chemotherapy was started. She completed 6 cycles of chemotherapy, but passed 
away only one month later. Case Rep Oncol 2011;4:426–432 
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10% of ovarian epithelial tumors consist of mucinous tumors. The vast majority of 
mucinous tumors are benign (75%), 10% borderline and 15% invasive carcinomas [4]. 
Mucinous tumors histologically resemble endocervical epithelium. They tend to remain 
confined to the ovaries for a longer period of time than serous carcinomas and are the 
largest epithelial ovarian neoplasms, with a median diameter of up to 20 cm. CA125 levels 
may not be markedly elevated, but tend to reflect the course of the disease.Three 
histopathological groups of mucinous tumors have been described: mucinous 
cystadenoma, mucinous tumor of uncertain malignant potential (borderline) and invasive 
mucinous carcinoma [5]. 
Mucinous borderline tumors produce large multicystic masses with smooth outer 
surfaces that may resemble benign mucinous cystadenomas. The majority of these tumors 
are unilateral, which is an important key to the histological diagnosis, because bilaterality 
of a mucinous tumor generally indicates the possibility of a metastatic tumor to the 
ovaries, derived from the appendix or other gastrointestinal sites, the pancreas or the 
endocervix, rather than a primary ovarian neoplasm. Furthermore, among unilateral 
tumors, size is an important diagnostic parameter. More than 80% of tumors larger than 
10 cm are ovarian primary tumors, whereas 88% of those smaller than 10 cm are 
metastases [4–7]. 
Pseudomyxoma peritonei is defined clinically on the basis of intraoperative findings as 
a grossly visible, localized, or generalized accumulation of mucus in the pelvis or 
abdomen, either lying on and attached to the peritoneal surfaces or incorporated within 
dense fibrous tissue [4, 6]. Ruptured mucinous tumors arising in ovarian mature cystic 
teratomas can produce voluminous ascites and a clinical picture of PMP. These 
teratomatous ovarian mucinous tumors probably represent the only cases of PMP 
originating from a primary ovarian tumor [1, 4, 6]. 
Typically borderline mucinous tumors are heterogeneous. They often contain areas of 
cystadenoma and noninvasive carcinoma, and occult areas of invasive carcinoma may 
also coexist. Therefore adequate sampling of mucinous tumors in the histology lab is 
especially important for the diagnosis. Tumors with a high-grade epithelial compound or 
an unclear level of invasion may require even more thorough sampling. Because of the 
large size of most borderline mucinous tumors, even extensive sampling may fail to detect 
a component of invasive carcinoma. Therefore histological samples at one block per 
centimeter are considered as a minimum [4, 8]. 
Immunohistochemistry may assist in determining the primary site of a mucinous 
carcinoma. Primary ovarian mucinous carcinomas are almost always immunoreactive for 
cytokeratin 7 (CK7) and cytokeratin 20 (CK20) with a predominance of CK7 expression. 
In contrast, colorectal carcinomas are strongly reactive for CK20 [2, 8]. K-RAS oncogene 
mutations are seen more frequently in mucinous ovarian carcinomas, whereas BRCA1 
and BRCA2 mutations are not. Mutations in the tumor suppressor gene p53, prominently 
involved in carcinogenesis of serous ovarian tumors, are rarely seen in mucinous tumors 
of the ovary. The carcinoembryonic antigen (CEA) serum tumor marker, typically 
associated with gastrointestinal carcinomas, is often elevated in mucinous ovarian 
tumors, whereas CA125 often remains low [4–8]. Case Rep Oncol 2011;4:426–432 
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Borderline ovarian tumors behave indolently in the overwhelming majority of cases, 
and the prognosis is therefore usually outstanding. One of the least known aspects of the 
natural history of borderline tumors is the development of an invasive carcinoma in 
patients with previous diagnosis of an ovarian borderline tumor. Zanetta et al. described a 
low risk of progression to invasive carcinoma of approximately 2%, both in mucinous and 
serous tumors [9]. Conservative management of a low malignant potential ovarian tumor 
significantly increases the risk of recurrence but does not affect overall survival [10–12]. 
There is increasing evidence that the pathogenesis of low-grade serous carcinomas and 
of serous tumors of low malignant potential (i.e., noninvasive borderline tumors) involves 
similar genes and pathways, and is distinct from that of high-grade serous carcinomas 
[13]. Clinical observations have been consistent with molecular and genomic 
investigations. Both tumor types are characterized by a young age at diagnosis and a 
prolonged natural history [14], and the clinical behavior of borderline tumors that recur 
as a low-grade invasive serous carcinoma appears similar to that of newly diagnosed low-
grade serous carcinomas [15]. These findings have led some authors to believe that low-
grade serous ovarian carcinomas are derived from undetected serous ovarian tumors of 
low malignant potential, although this hypothesis has not been proven. 
In the case described here, the clinical and immunohistochemical findings are 
consistent with a mucinous primary ovarian tumor associated with PMP. Generally 
recurrences of borderline tumors are treated successfully by surgical debulking [9–12]. In 
the current case secondary debulking was technically not achievable, hence our decision 
to start chemotherapy. It is remarkable that an invasive recurrence occurred after 
‘optimal’ surgical treatment of a borderline mucinous ovarian tumor. We therefore 
reiterated our initial histological analysis, but were unable to detect any invasive 
components in the original borderline tumor specimens. As hypothesized for low-grade 
serous carcinomas, we assume that mucinous borderline tumors may progress to invasive 
mucinous neoplasms. 
Conclusion 
We suggest a careful pathological sampling in case of a mucinous tumor. The use of 
clinical, pathological and immunohistochemical analyses together with tumor marker 
assays should help to correctly diagnose primary mucinous ovarian neoplasms. In case of 
borderline tumors we advocate careful follow-up, especially when a conservative surgical 
approach is selected. Recurrences can occur even 15 years later. A prolonged clinical 
follow-up supplemented with transvaginal ultrasound and tumor marker testing is 
advisable [9]. Even though the recurrence risk of mucinous borderline ovarian tumors is 
low, awareness of invasive recurrences of mucinous neoplasms is needed. 
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Fig. 1. Dermoid cyst. HES staining (×100) original magnification. 1: squamous epithelium, keratinized; 




Fig. 2. HES staining (×250). Gland with atypical mucinous epithelium with crowding 
pseudostratification and occasional mitotic figures (arrow). No invasion was found. 
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Fig. 4. CT scan: Axial view demonstrating the distribution of ascites and the filling of the umbilical 
herniation measuring 139 × 108 mm. 
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